1
|
Martinot M, Mohseni-Zadeh M, Gravier S, Ion C, Eyriey M, Beigue S, Coutan C, Ongagna JC, Henric A, Schieber A, Jochault L, Kempf C. Nosocomial Coronavirus Disease 2019 during 2020-2021: Role of Architecture and Ventilation. Healthcare (Basel) 2023; 12:46. [PMID: 38200952 PMCID: PMC10779121 DOI: 10.3390/healthcare12010046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2023] [Revised: 12/16/2023] [Accepted: 12/22/2023] [Indexed: 01/12/2024] Open
Abstract
Nosocomial coronavirus disease 2019 (COVID-19) is a major airborne health threat for inpatients. Architecture and ventilation are key elements to prevent nosocomial COVID-19 (NC), but real-life data are challenging to collect. We aimed to retrospectively assess the impact of the type of ventilation and the ratio of single/double rooms on the risk of NC (acquisition of COVID-19 at least 48 h after admission). This study was conducted in a tertiary hospital composed of two main structures (one historical and one modern), which were the sites of acquisition of NC: historical (H) (natural ventilation, 53% single rooms) or modern (M) hospital (double-flow mechanical ventilation, 91% single rooms). During the study period (1 October 2020 to 31 May 2021), 1020 patients presented with COVID-19, with 150 (14.7%) of them being NC (median delay of acquisition, 12 days). As compared with non-nosocomial cases, the patients with NC were older (79 years vs. 72 years; p < 0.001) and exhibited higher mortality risk (32.7% vs. 14.1%; p < 0.001). Among the 150 NC cases, 99.3% were diagnosed in H, mainly in four medical departments. A total of 73 cases were diagnosed in single rooms versus 77 in double rooms, including 26 secondary cases. Measured air changes per hour were lower in H than in M. We hypothesized that in H, SARS-CoV-2 transmission was favored by short-range transmission within a high ratio of double rooms, but also during clusters, via far-afield transmission through virus-laden aerosols favored by low air changes per hour. A better knowledge of the mechanism of airborne risk in healthcare establishments should lead to the implementation of corrective measures when necessary. People's health is improved using not only personal but also collective protective equipment, i.e., ventilation and architecture, thereby reinforcing the need to change institutional and professional practices.
Collapse
Affiliation(s)
- Martin Martinot
- Infectious Diseases Department, Hôpitaux Civils de Colmar, 68000 Colmar, France; (M.M.-Z.); (S.G.); (C.I.); (S.B.)
| | - Mahsa Mohseni-Zadeh
- Infectious Diseases Department, Hôpitaux Civils de Colmar, 68000 Colmar, France; (M.M.-Z.); (S.G.); (C.I.); (S.B.)
| | - Simon Gravier
- Infectious Diseases Department, Hôpitaux Civils de Colmar, 68000 Colmar, France; (M.M.-Z.); (S.G.); (C.I.); (S.B.)
| | - Ciprian Ion
- Infectious Diseases Department, Hôpitaux Civils de Colmar, 68000 Colmar, France; (M.M.-Z.); (S.G.); (C.I.); (S.B.)
| | - Magali Eyriey
- Clinical Research Department, Hôpitaux Civils de Colmar, 68000 Colmar, France; (M.E.); (J.-C.O.); (A.H.); (A.S.); (C.K.)
| | - Severine Beigue
- Infectious Diseases Department, Hôpitaux Civils de Colmar, 68000 Colmar, France; (M.M.-Z.); (S.G.); (C.I.); (S.B.)
| | - Christophe Coutan
- Technical Department, Hôpitaux Civils de Colmar, 68000 Colmar, France;
| | - Jean-Claude Ongagna
- Clinical Research Department, Hôpitaux Civils de Colmar, 68000 Colmar, France; (M.E.); (J.-C.O.); (A.H.); (A.S.); (C.K.)
| | - Anais Henric
- Clinical Research Department, Hôpitaux Civils de Colmar, 68000 Colmar, France; (M.E.); (J.-C.O.); (A.H.); (A.S.); (C.K.)
| | - Anne Schieber
- Clinical Research Department, Hôpitaux Civils de Colmar, 68000 Colmar, France; (M.E.); (J.-C.O.); (A.H.); (A.S.); (C.K.)
| | - Loic Jochault
- Medical Information Service, Hôpitaux Civils de Colmar, 68000 Colmar, France;
| | - Christian Kempf
- Clinical Research Department, Hôpitaux Civils de Colmar, 68000 Colmar, France; (M.E.); (J.-C.O.); (A.H.); (A.S.); (C.K.)
| |
Collapse
|
2
|
Lupia T, Corcione S, Shbaklo N, Boglione L, Torresan S, Pinna SM, Rizzello B, Bosio R, Fornari V, Brusa MT, Borrè S, De Rosa FG. Real-Life Experience of Molnupiravir in Hospitalized Patients Who Developed SARS-CoV2-Infection: Preliminary Results from CORACLE Registry. Antibiotics (Basel) 2022; 11:1541. [PMID: 36358196 PMCID: PMC9686801 DOI: 10.3390/antibiotics11111541] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2022] [Revised: 10/28/2022] [Accepted: 10/31/2022] [Indexed: 08/08/2023] Open
Abstract
Real-life experience of molnupiravir treatment is lacking, especially in people hospitalized for underlying diseases not related to COVID-19. We conducted a retrospective analysis regarding molnupiravir therapy in patients with SARS-CoV-2 infection admitted for underlying diseases not associated with COVID-19. Forty-four patients were included. The median age was 79 years (interquartile range [IQR]: 51-93 years), and most males were 57,4%. The median Charlson Comorbidity Index and 4C score were, respectively, 5 (IQR: 3-10) and 9.9 (IQR: 4-12). Moreover, 77.5% of the patients had at least two doses of the anti-SARS-CoV-2 vaccine, although 10.6% had not received any SARS-CoV-2 vaccine. Frequent comorbidities were cardiovascular diseases (68.1%), and diabetes (31.9%), and most admissions were for the acute chronic heart (20.4%) or liver (8.5%) failure. After molnupiravir started, 8 (18.1%) patients developed acute respiratory failure, and five (11.4%) patients died during hospitalisation. Moreover, molnupiravir treatment does not result in a statistically significant change in laboratory markers except for an increase in the monocyte count (p = 0.048, Z = 1.978). Molnupiravir treatment in our analysis was safe and well tolerated. In addition, no patients' characteristics were found significantly related to hospital mortality or an increase in oxygen support. The efficacy of the molecule remains controversial in large clinical studies, and further studies, including larger populations, are required to fill the gap in this issue.
Collapse
Affiliation(s)
- Tommaso Lupia
- Unit of Infectious Diseases, Cardinal Massaia, 14100 Asti, Italy
| | - Silvia Corcione
- Department of Medical Sciences, Infectious Diseases, University of Turin, 10126 Turin, Italy
- School of Medicine, Tufts University, Boston, MA 02111, USA
| | - Nour Shbaklo
- Department of Medical Sciences, Infectious Diseases, University of Turin, 10126 Turin, Italy
| | - Lucio Boglione
- Department of Translational Medicine (DiMET), University of Eastern Piedmont, Via Solaroli 17, 28100 Novara, Italy
| | - Stefano Torresan
- Department of Medical Sciences, Infectious Diseases, University of Turin, 10126 Turin, Italy
| | - Simone Mornese Pinna
- Department of Medical Sciences, Infectious Diseases, University of Turin, 10126 Turin, Italy
| | - Barbara Rizzello
- Department of Medical Sciences, Infectious Diseases, University of Turin, 10126 Turin, Italy
| | - Roberta Bosio
- Department of Medical Sciences, Infectious Diseases, University of Turin, 10126 Turin, Italy
| | - Valentina Fornari
- Department of Medical Sciences, Infectious Diseases, University of Turin, 10126 Turin, Italy
| | | | - Silvio Borrè
- Unit of Infectious Diseases, Saint Andrea Hospital, 13100 Vercelli, Italy
| | - Francesco Giuseppe De Rosa
- Unit of Infectious Diseases, Cardinal Massaia, 14100 Asti, Italy
- Department of Medical Sciences, Infectious Diseases, University of Turin, 10126 Turin, Italy
| |
Collapse
|